Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[177Lu]Lu-ACP
- Development stage
- Preclinical
- Lead developer
- University of Iowa
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
[177Lu]Lu-ACP is a preclinical radiopharmaceutical designed for the targeted radiotherapy of tumors expressing the calcitonin gene-related peptide receptor (CGRPR). The agent consists of a CGRPR-specific peptide bioconjugate, DOTA-Bn-NCS-FV-Tic-TDVGPFAF (ACP), radiolabeled with the beta-emitting isotope lutetium-177. CGRPR and its ligand CGRP are implicated in multiple hallmarks of cancer and are overexpressed in various primary malignancies. In preclinical studies, [177Lu]Lu-ACP demonstrated effective tumor targeting and significant tumor growth control in CGRPR-positive tumor models, suggesting its potential as a therapeutic component of a theranostic pair alongside imaging agents like [111In]In-ACP.
- Other names
- 177Lu-ACP[177Lu]Lu-DOTA-Bn-NCS-FV-Tic-TDVGPFAF
02
Targets
Calcitonin gene-related peptide type 1 receptor
Beyond the preview
Go deeper on [177Lu]Lu-ACP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [177Lu]Lu-ACP.